Burton-on-Trent, UK – 11 January 2012
Clinigen Group, a global specialty pharmaceutical products and pharma services business, has appointed Shaun Chilton as chief operating officer of the group’s services division, effective immediately. In this newly-created role, Mr Chilton will have overall leadership responsibility for Clinigen’s services division, incorporating two of Clinigen’s operations: Keats Healthcare, a clinical trial supply business acquired in 2010 (being re-branded as Clinigen CTS), and Clinigen GAP, a specialist provider of early-and late-lifecycle prescription drugs.
Mr Chilton, who will report to Clinigen Group’s chief executive, Peter George, has 20 years’ commercial, strategic and operational experience, including leadership, implementation and change-management roles in product-and service-oriented businesses. He joins Clinigen from KnowledgePoint360 Group, a global healthcare information and services provider, where he was president and managing director. While at KnowledgePoint360, he successfully repositioned the company’s Acumed and FireKite businesses, preparing the group for entry into the strategic consulting sector. He was responsible for identifying acquisition targets, overseeing post-transaction integrations and helping to expand the group’s international operations.
“Keats Healthcare and Clinigen GAP are already successful businesses providing standalone services, but they are highly complementary and synergies between the two companies make their combination into a services division compelling,” said Mr Chilton.
“The Keats business has clearly benefited from its recent alignment with the Clinigen brand,” added Mr Chilton. “And the market for global access programs, while underserved to date, is growing rapidly. Clinigen GAP is ideally positioned to capitalize on this opportunity. I am excited to be joining Clinigen at this pivotal stage of its development.”
Peter George said: “Shaun has a strong track record of building and leading high-performance sales and operational teams; driving commercial growth from international businesses; developing highly effective strategies, including major restructurings; and executing new strategies to deliver business goals, improve profitability and meet challenging targets. He will play a key role in helping us meet the ambitious objectives we have set for the Clinigen Group.”
About Shaun Chilton
Before joining KnowledgePoint360 Group, Shaun Chilton was global vice-president of medical communications at Wolters Kluwer Health, Pharma Solutions. He began his professional career in sales and marketing roles for Pfizer and Sanofi-Aventis (now Sanofi).
Mr Chilton holds a law degree from Reading University and postgraduate qualifications from Manchester Business School and the Kellogg School of Management at Northwestern University, Chicago.
Clinigen Group is a specialty pharmaceutical and pharma services company formed by merger in 2010. Clinigen Healthcare, a company established in 2007 by executive chairman Andy Leaver, acquires or in‐licenses mature or end‐of-lifecycle products for development and commercialization in hospitals. Clinigen Healthcare’s core therapeutic areas include oncology, leukaemia, hematology, transplantation, virology, pain management and critical care. The company also looks to acquire products that it can develop and commercialize in orphan indications.
Keats Healthcare (Clinigen CTS) became part of the Clinigen Group in 2010. Working in partnership with suppliers, pharmaceutical/biotech companies and contract research and manufacturing organizations, Keats sources commercial medicinal products for exclusive use in customers’ clinical studies, including comparator trials. Keats has exclusive supply agreements with top 10 pharmaceutical companies.
Clinigen GAP (Global Access Programs) provides tailored patient solutions, including named-patient, compassionate-use and early-access programs. Clinigen GAP services help to ensure that markets are primed, fully supported and supplied while customers’ products go through the regulatory and launch process. They also support the withdrawal or discontinuation of pharma companies’ end-of-lifecycle products.
Clinigen Group is headquartered in Burton-on-Trent, UK, with offices in Philadelphia, US, and Tokyo, Japan. In December 2011, Clinigen Group was named the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100. For more information visit: www.clinigengroup.com
Pete Chan at Tudor Reilly
Office: +44(0) 207 034 3208
Mobile: +44(0)7725 554 632